Dark

ENLV
Enlivex Ltd.
stock NASDAQ

Market Open

Jul 28, 2026 3:20:54 PM EDT

2.18USD-48.709%(-2.08)3,827,479

1.90Bid 2.22Ask 0.32Spread

Pre-market

Jul 24, 2026 8:41:30 AM EDT

4.36USD+3.810%(+0.16)0

After-hours

Jul 27, 2026 4:00:30 PM EDT

4.26USD+0.235%(+0.01)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 3, 2022

08:00AM EST ** Management to participate in a panel discussion: Innovative Approaches to Cell Therapy for Oncology, which is taking place on Friday, January 7th, at 8:30 AM ET ** GlobeNewswire Inc

Dec 13, 2021

08:03AM EST Enlivex Receives Regulatory Authorization To Expand Its Phase IIb Trial Evaluating Allocetra In Severe And Critical COVID-19 Patients Into Greece Benzinga

08:00AM EST Enlivex Receives Regulatory Authorization to Expand its Phase IIb GlobeNewswire Inc

Dec 7, 2021

08:04AM EST Enlivex Receives Regulatory Authorization To Expand Its Phase II Sepsis Trial Into Greece Benzinga

08:00AM EST Enlivex Receives Regulatory Authorization to Expand its Phase II GlobeNewswire Inc

Dec 6, 2021

08:15AM EST Enlivex Receives Notice Of Allowance For US Patent Application Covering Treatment Of Sepsis Patients With Allocetra Benzinga

08:00AM EST Enlivex Receives Notice of Allowance for U.S. Patent Application GlobeNewswire Inc

Nov 22, 2021

08:25AM EST Enlivex Q3 2021 R&D Expenses $2.679M Vs $1.122M YoY Benzinga

08:00AM EST Initiated dosing in placebo-controlled Phase IIb clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients with ARDS GlobeNewswire Inc

Nov 10, 2021

08:13AM EST Spanish Regulator Grants Enlivex Authorization To Expand Its Phase IIb Trial Evaluating Allocetra In Severe And Critical COVID-19 Patients Into Spain Benzinga

08:00AM EST Spanish Regulator Grants Enlivex Authorization to Expand its Phase GlobeNewswire Inc

Nov 4, 2021

08:23AM EDT Enlivex Therapeutics Reports Spanish Regulator Granted Co. Authorization To Expand Sepsis Phase 2 Trial Into Spain Benzinga

08:00AM EDT Spanish Regulator Grants Enlivex Authorization To Expand Its GlobeNewswire Inc

Oct 12, 2021

08:00AM EDT Publication follows the Israeli Ministry of Healths appointment of Prof. Mevorach as the lead investigator of a team evaluating side effects of COVID-19 vaccines GlobeNewswire Inc

Oct 5, 2021

08:18AM EDT Enlivex Receives Notice Of Allowance For Israeli Patent Application Covering Allocetra Derived From Pooled Donor Cells Benzinga

08:00AM EDT Enlivex Receives Notice of Allowance for Israeli Patent GlobeNewswire Inc

Oct 4, 2021

08:05AM EDT Enlivex Highlights Peer-Reviewed Publication In Frontiers In Immunology Of Clinical Data From Phase Ib Trial Evaluating Allocetra In Patients With Sepsis Benzinga

08:00AM EDT Enlivex Announces the Peer-Reviewed Publication in Frontiers in GlobeNewswire Inc

Sep 29, 2021

08:49AM EDT Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the Reuters Events' Cell & Gene Therapy USA 2021 event, which is taking place virtually on September 28 and 29, 2021. GlobeNewswire Inc

Sep 22, 2021

06:18AM EDT Enlivex Reports Initiation Of Dosing In Phase IIb Trial RTTNews

06:08AM EDT Enlivex Dosed First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS Benzinga

06:04AM EDT Enlivex Doses First Patient Allocetra Phase IIb Trial In COVID-19 Patients With Acute Respiratory Distress Syndrome RTTNews

06:04AM EDT Enlivex Dosed First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS Benzinga

06:00AM EDT Enlivex Doses First Patient in Placebo-Controlled Phase IIb GlobeNewswire Inc

Sep 9, 2021

08:00AM EDT Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that Company management will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021. GlobeNewswire Inc

Aug 16, 2021

02:32PM EDT Mid-Afternoon Market Update: Dow Turns Positive; Sesen Bio Shares Plummet Benzinga

12:13PM EDT Mid-Day Market Update: Crude Oil Down Over 2%; Travere Therapeutics Shares Jump Benzinga

10:00AM EDT Shares of Enlivex Therapeutics Ltd. (ENLV) are surging more than 19% Monday morning after the company's drug candidate Allocetra received clearance to start Phase 2b study in severe and critical COVID-19 patients in Israel. RTTNews

08:57AM EDT Benzinga Pro's Top 5 Stocks To Watch For Monday, Aug. 16, 2021: MGI, ENLV, GNUS, PCG, FATE Benzinga

05:45AM EDT Enlivex Therapeutics Shares Rise 22% Premarket; Co Reported Sunday After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of a Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients Benzinga

Aug 15, 2021

06:00AM EDT Enlivex: After Review of Phase II Data, Israeli Ministry of Health GlobeNewswire Inc

Aug 9, 2021

08:18AM EDT Enlivex Therapeutics Reports Q2 Net Loss Of $3.108M Vs. $3.041M YoY Benzinga

08:00AM EDT Enlivex Announces Second Quarter 2021 Financial Results and GlobeNewswire Inc

Aug 2, 2021

08:00AM EDT Mr. Palash joins Enlivex from Gamida Cell, where he served as Chief Operating Officer, and previously served as Chief Operating Officer of Protalix Biotherapeutics, and as General Manager of ColBar LifeScience, a Johnson & Johnson company GlobeNewswire Inc

Jul 21, 2021

08:00AM EDT Enlivex to Present at the Improvate Life-Saving Technologies GlobeNewswire Inc

Jul 14, 2021

08:00AM EDT Enlivex to Present at the ARDS Drug Development Summit 2021 GlobeNewswire Inc

Jul 12, 2021

08:11AM EDT Enlivex Initiates Design And Construction Process For A New cGMP Allocetra Manufacturing Plant Benzinga

08:00AM EDT Enlivex Initiates Design and Construction Process for a New cGMP GlobeNewswire Inc

Jun 16, 2021

08:00AM EDT Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming immunotherapy company, today announced that members of the Companys management team will participate in A.G.P.s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021. GlobeNewswire Inc

Jun 15, 2021

08:04AM EDT Enlivex Announces Issuance Of New European Patent Titled 'Combination Immune Therapy And Cytokine Control Therapy For Cancer Treatment' Benzinga

08:00AM EDT Enlivex Announces Issuance of New European Patent Covering GlobeNewswire Inc

Jun 11, 2021

03:14PM EDT Enlivex Earlier National Institutes Of Health ClinicalTrials.gov Study Record Detail For Co.'s 'Phase 2b...Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19...' Benzinga

Jun 3, 2021

08:00AM EDT Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the Jefferies 2021 Virtual Healthcare Conference on June 4, 2021, 10:00 EDT. The presentation will be available through the conference website, at https://wsw.com/webcast/jeff174/enlv/1861731. GlobeNewswire Inc

Jun 1, 2021

08:06AM EDT Enlivex Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses Of Allocetra Immunotherapy Benzinga

08:00AM EDT Enlivex Announces Issuance of New Canadian Patent Covering GlobeNewswire Inc

May 18, 2021

08:15AM EDT Enlivex Says Awarded Second Israel Innovation Authority Grant To Support Clinical Development Of Allocetra In Sepsis; Says Grant Provides $1.1M In Funding Benzinga

08:00AM EDT Enlivex Awarded Second Israel Innovation Authority Grant to GlobeNewswire Inc

May 11, 2021

10:30AM EDT Enlivex Therapeutics Granted U.S. Patent Titled 'Combination immune therapy and cytokine control therapy for cancer treatment' Benzinga

Mar 22, 2021

12:54PM EDT Enlivex To Study Allocetra Combined With Checkpoint Inhibitors In Solid Tumor Settings Benzinga

08:02AM EDT Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra in Combination with Immune Checkpoint Inhibitors Benzinga

08:00AM EDT Enlivex Announces Research Collaboration with Yale Cancer Center GlobeNewswire Inc

Mar 9, 2021

08:00AM EST Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the following investor conferences: GlobeNewswire Inc

Mar 8, 2021

08:46AM EST Enlivex Receives Notice of Allowance for Japanese Patent GlobeNewswire Inc

08:27AM EST Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR-T Therapies Benzinga

Mar 1, 2021

07:56AM EST Enlivex And Mount Sinai Health System Announce Research Collaboration For Development Of Allocetra In Combination With Immune Checkpoint Inhibitors; Financial Details Not Disclosed Benzinga

07:55AM EST -- Collaboration aims to evaluate the potential of Allocetra in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor therapies -- GlobeNewswire Inc

Feb 22, 2021

08:08AM EST Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy Benzinga

08:00AM EST Enlivex Receives Notice of Allowance for Chinese Patent GlobeNewswire Inc

Feb 18, 2021

08:00AM EST Enlivex Announces Exercise of Underwriters GlobeNewswire Inc

Feb 16, 2021

08:30AM EST Enlivex Announces Issuance of New U.S. Patent Covering Methods of GlobeNewswire Inc

Feb 12, 2021

05:21PM EST Enlivex Announces Closing of Previously Announced Bought Deal GlobeNewswire Inc

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 9, 2021

11:33PM EST Enlivex Increases Bought Deal Offering To About $46.0 Mln Of Ordinary Shares RTTNews

11:25PM EST Enlivex Increases Previously Announced Bought Deal Offering to GlobeNewswire Inc

05:27PM EST Enlivex Announces $10M Bought Deal Offering Of 500K Ordinary Shares At $20/Share Benzinga

05:26PM EST Enlivex Announces $10 Million Bought Deal Offering of Ordinary Shares GlobeNewswire Inc

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 3, 2021

12:34PM EST Enlivex Rallies On Encouraging Allocetra Data In Mid-Stage COVID-19 Study Benzinga

09:59AM EST Shares of Enlivex Therapeutics Ltd. (ENLV) are rising more than 14% after the company reported positive top line results from the phase II study of its drug candidate Allocetra in severe and critical Covid-19 patients. RTTNews

07:57AM EST Enlivex Reports Top-Line Results From Phase II Clinical Trial Evaluating Allocetra In Severe And Critical COVID-19 Patients Benzinga

07:55AM EST Enlivex Reports Positive Top-Line Results from Phase II Clinical GlobeNewswire Inc

Jan 11, 2021

08:00AM EST Enlivex to Present at the H.C. Wainwright BioConnect 2021 Virtual GlobeNewswire Inc

Dec 21, 2020

08:00AM EST Comparison of 10 AllocetraTM-treated patients with 37 matched controls showed significant positive responses in state of organ failure, duration of ICU stay and mortality in a highly fragile and extremely difficult to treat population with severe sepsis GlobeNewswire Inc

Dec 7, 2020

08:17AM EST Enlivex Announces Issuance Of New Chinese Patent Covering Allocetra Immunotherapy Benzinga

08:00AM EST Enlivex Announces Issuance of New Chinese Patent Covering GlobeNewswire Inc

Dec 3, 2020

01:09PM EST Why Sutro, Lumos And More Health Care Stocks Are Moving Today Benzinga

08:00AM EST Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage immunotherapy company, today reported positive interim results of an investigator-initiated Phase II clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients. GlobeNewswire Inc

Nov 18, 2020

08:04AM EST Enlivex Reports Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated With Allocetra Benzinga

08:00AM EST * Significant short and long-term clinical improvement for a hospitalized patient with a rare disease that currently has no effective treatment options * GlobeNewswire Inc

Nov 17, 2020

08:18AM EST * Dr. Schwartz Served as ArQules Chief Medical Officer and Head of Research and Development Prior to the $2.7 billion Acquisition of ArQule by Merck in February 2020 * GlobeNewswire Inc

Nov 11, 2020

08:14AM EST Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage immunotherapy company, today announced that it will present the clinical development schedule for its Sepsis, COVID-19 and Solid Cancer programs during a fireside chat at H.C. Wainwrights 6th Annual Israel Conference. See below for more details. GlobeNewswire Inc

Nov 9, 2020

10:24AM EST Shares of Enlivex Therapeutics Ltd. (ENLV) tanked over 22% on Monday morning despite no stock-related news. RTTNews

Nov 5, 2020

08:40AM EST Enlivex Reports Notice Of Allowance For US Patent Application Covering Methods Of Treating Gout, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis With Allocetra Immunotherapy Benzinga

Nov 3, 2020

09:14AM EST Enlivex Reports Israeli Ministry Of Health Authorizes Initiation Of Phase IIb Clinical Trial Evaluating Safety And Efficacy Of Allocetra In Sepsis Patients Benzinga

09:12AM EST Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage immunotherapy company, today reported that the Israeli Ministry of Health authorized the initiation of a proposed Company-sponsored Phase IIb clinical trial evaluating Allocetra, in sepsis patients. GlobeNewswire Inc

Oct 27, 2020

08:00AM EDT * Findings and Analyses On 68,000 COVID-19 Patients Discussed in the Webinar on Thursday, November 5th @ 10amET * GlobeNewswire Inc

Oct 22, 2020

08:46AM EDT Enlivex Therapeutics Reports Dosing Of First 2 Patients In Phase 2 Trial Evaluating Allocetra In Severe, Critical COVID-19 Patients Benzinga

08:45AM EDT Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage immunotherapy company, today reported that the first two patients have been dosed in an investigator-initiated Phase II clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients. GlobeNewswire Inc

Oct 13, 2020

09:28AM EDT Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage immunotherapy company, today reported that the Israeli Ministry of Health authorized the initiation of a proposed investigator-initiated Phase II clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients. GlobeNewswire Inc

Oct 7, 2020

10:41AM EDT Enlivex Therapeutics Ltd. (ENLV) shares are sliding more than 12 percent on Wednesday morning, despite no specific announcement from the company. RTTNews

Oct 5, 2020

09:55AM EDT Shares of Enlivex Therapeutics Ltd. (ENLV) are up more than 30% Monday morning, continuing the momentum following positive Covid-19 drug results. RTTNews

Oct 1, 2020

12:39PM EDT Mid-Day Market Update: Crude Oil Down 5.5%; Solid Biosciences Shares Jump Benzinga

10:42AM EDT Mid-Morning Market Update: Markets Open Higher; PepsiCo Beats Q3 Views Benzinga

10:14AM EDT Shares of clinical-stage immunotherapy company, Enlivex Therapeutics Ltd. (ENLV) are surging nearly 70% Thursday morning after the company reported positive top-line results from the study of its Covid-19 drug candidate, Allocetra. RTTNews

06:52AM EDT A Peek Into The Markets: US Stock Futures Surge; PepsiCo Tops Q3 Views Benzinga

06:36AM EDT Enlivex Reports Positive Top-line Results From RTTNews

06:11AM EDT Enlivex Reports Positive Top-line Results Of Investigator-initiated Clinical Trial Of Allocetra RTTNews

06:04AM EDT Enlivex Announces Positive Trial Results For Its Allcetra In Coronavirus Patients In Severe/Critical Condition Benzinga

06:00AM EDT Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage immunotherapy company, today reported positive top-line results of an investigator-initiated clinical trial of AllocetraTMin COVID-19 patients in severe/critical condition. GlobeNewswire Inc

Sep 16, 2020

08:14AM EDT Enlivex Announces Allowance Of New Chinese Patent Covering Allocetra Immunotherapy Benzinga

08:01AM EDT Enlivex Announces Allowance of New Chinese Patent Covering GlobeNewswire Inc

Aug 25, 2020

08:05AM EDT Enlivex Announces Allowance Of New US Patent Covering Allocetra Immunotherapy Benzinga

08:00AM EDT Enlivex Announces Allowance of New U.S. Patent Covering Allocetra GlobeNewswire Inc

Aug 10, 2020

08:20AM EDT Enlivex Says First Patient Dosed In Clinical Trial Of Allocetra In COVID-19 Patients RTTNews

08:01AM EDT Enlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure Benzinga

08:00AM EDT Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the first patient has been dosed in an investigator-initiated multi-center clinical trial of AllocetraTM in COVID-19 patients with severe illness and respiratory failures. GlobeNewswire Inc

Jul 20, 2020

08:20AM EDT - Data show a 90% decrease in mortality with AllocetraTM treatment in a murine cecal ligation and puncture severe sepsis model GlobeNewswire Inc

.dark-mode .GS6Yvm{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .GS6Yvm{ color: #333333; background-color: white; border: 2px solid #333333; }ENLVEnlivex Ltd.stock NASDAQ

ENLV
Enlivex Ltd.
stock NASDAQ